Overall, the results demonstrated that only two cycles of therapy are required for limited stage disease, therapy could be reduced in intensity for intermediate risk disease but that patients with most advanced disease (bone marrow [BM] ± central nervous system [CNS] disease) require full intensity FAB/LMB 96 therapy)